References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPrevalence of vitamin D inadequacy in European women aged over 80 years
Bruyère, Olivier ULg; Slomian, Justine ULg; Beaudart, Charlotte ULg et al

in Archives of Gerontology & Geriatrics (2014), 59

Inadequate vitamin D status is associated with secondary hyperparathyroidism and increased bone turnover and bone loss, which in turn increases fracture risk. The objective of this study is to assess the ... [more ▼]

Inadequate vitamin D status is associated with secondary hyperparathyroidism and increased bone turnover and bone loss, which in turn increases fracture risk. The objective of this study is to assess the prevalence of inadequate vitamin D status in European women aged over 80 years. Assessments of serum 25-hydroxyvitamin D levels (25(OH)D) were performed on 8532 European women with osteoporosis or osteopenia of which 1984 were aged over 80 years. European countries included in the study were: France, Belgium, Denmark, Italy, Poland, Hungary, United Kingdom, Spain and Germany. Two cut-offs of 25(OH)D inadequacy were fixed: <75 nmol/L (30 ng/ml) and <50 nmol/L (20 ng/ml). Mean (SD) age of the patients was 83.4 (2.9) years, body mass index was 25.0 (4.0) kg/m2 and level of 25(OH)D was 53.3 (26.7) nmol/L (21.4 [10.7] ng/ml). There was a highly significant difference of 25(OH)D level across European countries (p < 0.0001). In these women aged over 80 years, the prevalence of 25(OH)D inadequacy was 80.9% and 44.5% when considering cut-offs of 75 and 50 nmol/L, respectively. In the 397 (20.0%) patients taking supplemental vitamin D with or without supplemental calcium, the mean serum 25(OH)D level was significantly higher than in the other patients (65.2 (29.2) nmol/L vs. 50.3 (25.2) nmol/L; P < 0.001). This study indicates a high prevalence of vitamin D (25(OH)D) inadequacy in old European women. The prevalence could be even higher in some particular countries. [less ▲]

Detailed reference viewed: 28 (12 ULg)
Full Text
Peer Reviewed
See detailEffects of vitamin D in the elderly population : current status and perspectives
Bruyère, Olivier ULg; CAVALIER, Etienne ULg; Souberbielle, JC et al

in Archives of Public Health (2014), 72

Besides its well-known effect on bone metabolism, recent researches suggest that vitamin D may also play a role in the muscular, immune, endocrine, and central nervous systems. Double-blind RCTs support ... [more ▼]

Besides its well-known effect on bone metabolism, recent researches suggest that vitamin D may also play a role in the muscular, immune, endocrine, and central nervous systems. Double-blind RCTs support vitamin D supplementation at a dose of 800 IU per day for the prevention of falls and fractures in the senior population. Ecological, case–control and cohort studies have suggested that high vitamin D levels were associated with a reduced risk of autoimmune diseases, type 2 diabetes, cardio-vascular diseases and cancer but large clinical trials are lacking today to provide solid evidence of a vitamin D benefit beyond bone health. At last, the optimal dose, route of administration, dosing interval and duration of vitamin D supplementation at a specific target dose beyond the prevention of vitamin D deficiency need to be further investigated. [less ▲]

Detailed reference viewed: 32 (7 ULg)
Full Text
Peer Reviewed
See detailTraitement de l'osteoporose post-menopausique: quoi de neuf en 2014?
Reginster, Jean-Yves ULg; Neuprez, A.; Lecart, M. P. et al

in Revue medicale de Liege (2014), 69(7-8), 441-53

Management of osteoporosis involves both non pharmacological approaches, including changes in lifestyle and dietary habits combined, in patients at high risk of fracture or presenting with an established ... [more ▼]

Management of osteoporosis involves both non pharmacological approaches, including changes in lifestyle and dietary habits combined, in patients at high risk of fracture or presenting with an established osteoporosis, to the use of drugs. Besides supplementation in calcium and vitamin D (at daily doses of 1 gr and 800 IU) in patients whose dietary intakes do not cover the recommended daily allowances, medications to be used for the management of osteoporosis may include inhibitors of bone resorption (bisphosphonates, denosumab and selective estrogen receptor modulators), stimulators of bone formation (teriparatide) or chemical entities decreasing bone resorption and stimulating bone formation (strontium ranelate). The selection of a particular medication, for a single individual patient, will depend on the severity of the disease as well as on the patient's believes and expectations. Local, skeletal and systemic tolerance of the various drugs should also be taken into account. [less ▲]

Detailed reference viewed: 28 (7 ULg)
Full Text
Peer Reviewed
See detailThe role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women : A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
Rizzoli, R; Stevenson, JC; Bauer, JM et al

in Maturitas (2014), 79

From 50 years of age, postmenopausal women are at an increased risk of developing sarcopenia and osteoporosis as a result of deterioration of musculoskeletal health. Both disorders increase the risk of ... [more ▼]

From 50 years of age, postmenopausal women are at an increased risk of developing sarcopenia and osteoporosis as a result of deterioration of musculoskeletal health. Both disorders increase the risk of falls and fractures. The risk of developing sarcopenia and osteoporosis may be attenuated through healthy lifestyle changes, which include adequate dietary protein, calcium and vitamin D intakes, and regular physical activity/exercise, besides hormone replacement therapy when appropriate. Protein intake and physical activity are the main anabolic stimuli for muscle protein synthesis. Exercise training leads to increased muscle mass and strength, and the combination of optimal protein intake and exercise produces a greater degree of muscle protein accretion than either intervention alone. Similarly, adequate dietary protein intake and resistance exercise are important contributors to the maintenance of bone strength. Vitamin D helps to maintain muscle mass and strength as well as bone health. These findings suggest that healthy lifestyle measures in women aged >50 years are essential to allow healthy ageing. The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) recommends optimal dietary protein intake of 1.0–1.2 g/kg body weight/d with at least 20–25 g of high-quality protein at each main meal, with adequate vitamin D intake at 800 IU/d to maintain serum 25-hydroxyvitamin D levels >50 nmol/L as well as calcium intake of 1000 mg/d, alongside regular physical activity/exercise 3–5 times/week combined with protein intake in close proximity to exercise, in postmenopausal women for prevention of age-related deterioration of musculoskeletal health. [less ▲]

Detailed reference viewed: 25 (2 ULg)
Full Text
Peer Reviewed
See detailReturn-to-play critera after hamstring injury: actual medicine practice professional soccer teams
Delvaux, François ULg; Rochcongar, p; Bruyère, Olivier ULg et al

in Journal of Sports Science & Medicine (2014), 13

Detailed reference viewed: 15 (3 ULg)
Full Text
Peer Reviewed
See detailEffect of denosumab treatment in postmenopausal women with osteoporosis: eight-year results from the freedom extension, phase 3 clinical trial
Lewieck, E; Papapoulos, S; Lippuner, K et al

in Endocrine Reviews (2014), 35(3), 22-1

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailDenosumab for the treatment of men with low bone mineral density: 24-month results from the Adamo Trial
Langdahl, B; Teglbjaerg, C; Ho, PR et al

in Endocrine Reviews (2014), 35(3), 22-1

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailThe quantified patient: a patient participatory culture.
Appelboom, Geoff; LoPresti, Melissa; Reginster, Jean-Yves ULg et al

in Current medical research and opinion (2014)

Abstract The Quantified Self Movement, which aims to improve various aspects of life and health through recording and reviewing daily activities and biometrics, is a new and upcoming practice of self ... [more ▼]

Abstract The Quantified Self Movement, which aims to improve various aspects of life and health through recording and reviewing daily activities and biometrics, is a new and upcoming practice of self monitoring that holds much promise. Now, the most underutilized resource in ambulatory health care, the patient, can participate like never before, and the patient's Quantified Self can be directly monitored and remotely accessed by health care professionals. [less ▲]

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailSmart wearable body sensors for patient self-assessment and monitoring
Appelboom, G; Camacho, E; Abraham, M et al

in Archives of Public Health (2014), 72

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailCardiac concerns associated with strontium ranelate.
Reginster, Jean-Yves ULg

in Expert opinion on drug safety (2014), 13(9), 1-5

Introduction: Strontium ranelate is proven to reduce vertebral and non-vertebral fracture risk in osteoporosis. Concerns about cardiac safety have led to a new contraindication to strontium ranelate in ... [more ▼]

Introduction: Strontium ranelate is proven to reduce vertebral and non-vertebral fracture risk in osteoporosis. Concerns about cardiac safety have led to a new contraindication to strontium ranelate in patients with uncontrolled hypertension and/or current or past history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease. Areas covered: A literature search was performed; data were also collected from the European Medicines Agency website. Randomised controlled trial (RCT) data indicate a higher incidence of non-adjudicated myocardial infarction (MI) with strontium ranelate versus placebo (1.7 vs 1.1%; odds ratio [OR]: 1.6; 95% CI: 1.07 - 2.38; p = 0.020) (Mantel-Haenzel estimate of the OR). There was no increase in cardiovascular mortality. MI risk was mitigated by excluding patients with cardiovascular contraindications (OR: 0.99; 95% CI: 0.48 - 2.04; p = 0.988). Three observational studies performed in the context of real-life medical practice in the UK and Denmark did not report a signal. Expert opinion: The increased risk for cardiac events with strontium ranelate has been detected in RCTs but not in real life. Excluding patients with cardiovascular contraindications appears to be an effective measure for controlling the risk of MI. Strontium ranelate remains a useful therapeutic alternative in patients with severe osteoporosis without cardiovascular contraindications who are unable to take another osteoporosis treatment. [less ▲]

Detailed reference viewed: 9 (3 ULg)
Full Text
Peer Reviewed
See detailIndirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.
Ellis, Alexandra G.; Reginster, Jean-Yves ULg; Luo, Xuemei et al

in Current medical research and opinion (2014), 30(8), 1617-1626

Abstract Objective: Compare the efficacy of bazedoxifene with oral bisphosphonates for reduction of vertebral fracture risk in postmenopausal osteoporotic (PMO) women and in higher-risk patients based on ... [more ▼]

Abstract Objective: Compare the efficacy of bazedoxifene with oral bisphosphonates for reduction of vertebral fracture risk in postmenopausal osteoporotic (PMO) women and in higher-risk patients based on evidence from randomized controlled trials (RCTs). Methods: Eight RCTs assessing vertebral fracture risk reduction with oral bisphosphonates (n = 7) or bazedoxifene (n = 1) were identified by a systematic literature review. Individual study results were pooled in a network meta-analysis (NMA) to indirectly compare treatment effects for overall PMO women and a higher-risk subgroup (FRAX >/= 20%). Three sets of NMA analyses were conducted: aggregate data (AD) from the bisphosphonate RCTs and bazedoxifene RCT for the full population or the FRAX >/=20% subgroup (NMA AD); bisphosphonate AD and bazedoxifene AD from each FRAX subgroup adjusted for baseline risk (NMA AD meta-regression); and bisphosphonate AD and bazedoxifene individual patient data (IPD) adjusted for baseline risk/FRAX (NMA AD/IPD meta-regression). Results: For the overall population, bisphosphonates had lower fracture risks versus bazedoxifene although there is considerable uncertainty in supporting one intervention over another. The relative risk reduction (RRR) for bazedoxifene was -0.23 (95% CrI: -1.11, 0.27) versus ibandronate, -0.17 (-0.76, 0.22) versus alendronate, and -0.06 (-0.62, 0.30) versus risedronate. Results from the meta-regression analyses were similar. For the FRAX >/=20% population, estimated fracture rates with bazedoxifene were lower than with bisphosphonates, but again the uncertainty limits strong interpretation. The RRR for bazedoxifene was 0.51 (-0.31, 0.83) versus ibandronate, 0.53 (-0.18, 0.83) versus alendronate, and 0.57 (-0.07, 0.85) versus risedronate. The meta-regression analyses showed comparable findings. Conclusion: The analyses only considered vertebral fractures for oral bisphosphonates versus bazedoxifene, and IPD was available only for bazedoxifene. In light of this, bazedoxifene is comparable to bisphosphonates in the overall PMO population and at least as effective as bisphosphonates for preventing vertebral fractures among higher-risk PMO patients. The findings suggest bazedoxifene performs better in higher-risk PMO than in the overall PMO. [less ▲]

Detailed reference viewed: 15 (7 ULg)
Full Text
Peer Reviewed
See detailBone forming agents for the management of osteoporosis
Reginster, Jean-Yves ULg; Neuprez, A.; Beaudart, Charlotte ULg et al

in Panminerva medica (2014), 56(2), 97-114

Osteoporotic fractures are a major cause of morbidity in the population. Anti-resorptive agents have been, for more than 15 years, the mainstay of osteoporosis treatment worldwide. However, these ... [more ▼]

Osteoporotic fractures are a major cause of morbidity in the population. Anti-resorptive agents have been, for more than 15 years, the mainstay of osteoporosis treatment worldwide. However, these medications provide only limited fracture reduction and may be linked to skeletal and non-skeletal long-term safety concerns. Therefore, some patients are considered candidates for bone-forming agents because they remain severely osteoporotic or because they failed antiresorptive therapy. Over the last decade, a particular interest was shown in the developmentofmedicationsabletoincreaseosteoblastsnumber,lifespan or activity, hence stimulating bone formation Peptides from the parathyroid hormone family and strontium ranelate were shown to significantly reduce fracture rates but strontium ranelate is no longer an option for treating osteoporosis because of its safety profile. New therapeutic options, including monoclonal antibodies against sclerostin seem to be promising but their role in the armamentarium of osteoporosis will depend on the results of the current phase 3 studies, assessing antifracture efficacy and long-term safety. [less ▲]

Detailed reference viewed: 24 (11 ULg)
Full Text
Peer Reviewed
See detailImpact of components of the metabolic syndrome on progression of knee osteoarthritis in the SEKOIA study
Edwards, MH; Parsons, C; Eymard, F et al

in Rheumatology (2014), 53(1), 31

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailImpact of bone marrow lesion on the progression of knee osteoarthritis in the SEKOIA study
Parsons, C; Edwards, MH; Bruyère, Olivier ULg et al

in Rheumatology (2014), 53(1), 130

Detailed reference viewed: 10 (5 ULg)
Full Text
Peer Reviewed
See detailTeriparatide Therapy for Denosumab-Induced Osteonecrosis of the Jaw in a Male Osteoporotic Patient.
Neuprez, Audrey; Rompen, Eric ULg; Crielaard, Jean-Michel ULg et al

in Calcified tissue international (2014), 95

We report the first case of teriparatide adjuvant role in the management of a denosumab-induced osteonecrosis of the jaw in a male subject with idiopathic osteoporosis. Clinical benefits and CT healing ... [more ▼]

We report the first case of teriparatide adjuvant role in the management of a denosumab-induced osteonecrosis of the jaw in a male subject with idiopathic osteoporosis. Clinical benefits and CT healing were obtained within 2 months of teriparatide initiation and denosumab withdrawal. Increase in bone turnover previously described, when denosumab treatment is removed, might have a synergistic effect to the stimulating effect of teriparatide on bone remodeling to promptly heal osteonecrosis of the jaw. [less ▲]

Detailed reference viewed: 12 (5 ULg)
Full Text
Peer Reviewed
See detailAntiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis.
Reginster, Jean-Yves ULg; Neuprez, A.; Beaudart, Charlotte ULg et al

in Drugs & aging (2014), 31

Osteoporotic fractures are a major cause of morbidity in the elderly population. Since postmenopausal osteoporosis is related to an increase in osteoclastic activity at the time of menopause, inhibitors ... [more ▼]

Osteoporotic fractures are a major cause of morbidity in the elderly population. Since postmenopausal osteoporosis is related to an increase in osteoclastic activity at the time of menopause, inhibitors of bone resorption have genuinely been considered an adequate strategy for prevention and treatment of osteoporosis. Bisphosphonates and selective oestrogen receptor modulators are widely prescribed to treat osteoporosis. However, other antiresorptive drugs have been developed for the management of osteoporosis, with the objective of providing a substantial reduction in osteoporotic fractures at all skeletal sites, combined with an acceptable long-term skeletal and systemic safety profile. Denosumab, a human monoclonal antibody to receptor activator for nuclear factor kappa B ligand, has shown efficacy against vertebral, nonvertebral and hip fractures. Its administration every 6 months as a subcutaneous formulation might significantly influence compliance and persistence to therapy. Additional results regarding long-term skeletal safety (i.e. osteonecrosis of the jaw and atypical diaphyseal femoral fracture) are needed. Odanacatib, a selective cathepsin K inhibitor, is a promising new approach to the inhibition of osteoclastic resorption, with the potential to uncouple bone formation from bone resorption. Results regarding its anti-fracture efficacy are expected in the coming months. [less ▲]

Detailed reference viewed: 20 (6 ULg)
Full Text
Peer Reviewed
See detailSarcopénie. Quoi de neuf en 2014 ?
Beaudart, Charlotte ULg; GILLAIN, Sophie ULg; Petermans, Jean ULg et al

in Revue Médicale de Liège (2014), 69(5-6), 251-257

Detailed reference viewed: 36 (12 ULg)
Full Text
Peer Reviewed
See detailCan new information and communication technologies help in the management of osteoporosis ?
Slomian, Justine ULg; Appelboom, G; Ethgen, Olivier ULg et al

in Women's Health (2014), 10(3), 229-232

Detailed reference viewed: 21 (4 ULg)